Expression of CD56 is an unfavorable prognostic factor for acute promyelocytic leukemia with higher initial white blood cell counts

• DOI: 10.1111/cas.12319
• Publication Date: 2013-11-11T03:32:47Z
• Authors: Takaaki Ono; Akihiro Takeshita; Yuji Kishimoto; Hitoshi Kiyoi; Masaya Okada; Takahiro Yamauchi; Nobuhiko Emi; Kentaro Horikawa; Mitsuhiro Matsuda; Katsuji Shinagawa; Fumihiko Monma; Shigeki Ohtake; Chiaki Nakaseko; Masatomo Takahashi; Yukihiko Kimura; Masako Iwanaga; Norio Asou; Tomoki Naoe
• Keywords: White blood cell; Cumulative incidence; Clinical Significance

Expression of CD56 has recently been introduced as one the adverse prognostic factors in acute promyelocytic leukemia (APL). However, clinical significance antigen APL not well elucidated. We assessed 239 patients prospectively treated with all-trans retinoic acid and chemotherapy according to Japan Adult Leukemia Study Group APL97 protocol. All were by The median follow-up period was 8.5 years. Positive expression found 23 (9.6%). significantly associated lower platelet count (P = 0.04), severe disseminated intravascular coagulation coexpression CD2 0.03), CD7 CD34 < 0.01) and/or human leukocyte antigen-DR 0.01). Complete remission rate overall survival different between two groups. cumulative incidence relapse event-free (EFS) showed an inferior trend CD56(+) 0.08 P 0.08, respectively). Among initial white blood cell counts 3.0 × 10(9)/L or more, EFS worse (30.8% vs 63.6%, 0.008, 53.8% 28.9%, 0.03, respectively), multivariate analysis, unfavorable factor for 0.04). In conclusion, higher counts, should be regarded factor.